Theratechnologies (THTX) said Tuesday it received US Food and Drug Administration approval of its Prior Approval Supplement to the supplemental biologics license application for Egrifta SV, or tesamorelin, used to reduce excess abdominal fat in adults with HIV and lipodystrophy.
The approval removes the need for discretionary product release, allowing the company to resume normal distribution of Egrifta SV.
The FDA also recently approved a new F8 formulation of tesamorelin, to be marketed as Egrifta WR, which will replace Egrifta SV in the US.
Safety considerations include unestablished long-term cardiovascular effects, a weight-neutral profile, and no evidence of improved adherence to antiretroviral therapy, the company said.
Shares of Theratechnologies were up more than 5% in recent trading.
Price: 1.73, Change: +0.09, Percent Change: +5.18
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。